TY - EJOU
AU - Ertas, Kemal
AU - Tahiroglu, Veysel
AU - Karagecili, Hasan
AU - Yerlikaya, Emrah
AU - Erkan, Revsa Evin Canpolat
AU - Coskun, Erkam
TI - Association between serum spermidine synthase levels and acquired premature ejaculation: a cross-sectional study
T2 - Canadian Journal of Urology
PY -
VL -
IS -
SN - 1488-5581
AB - Background: Premature ejaculation (PE), the most common male sexual dysfunction worldwide, has a pathophysiology that is not fully understood and lacks reliable biomarkers. Recent studies suggest a potential role for polyamine metabolism in neuroregulation and sexual function. This study investigated the association between serum spermidine synthase (SRM) levels and acquired PE. Methods: In this prospective cross-sectional study conducted at Sirnak State Hospital between March and August 2024, 82 men (43 patients with acquired PE and 39 age-matched controls) were evaluated. Intravaginal ejaculation latency time (IELT) was measured by stopwatch (patient and/or partner-assisted), metabolic parameters were assessed, and serum SRM levels were quantified using a human-specific sandwich Enzyme-linked immunosorbent assay (ELISA) kit (research-use-only, detection range 75–5000 pg/mL). Statistical analyses included the Mann-Whitney U test, Student t-test, and Spearman correlation. Results: PE patients exhibited significantly lower SRM levels (141 vs. 189 pg/mL, p = 0.016), markedly shorter IELT (96 vs. 180 s, p < 0.001), higher triglycerides (156 vs. 78 mg/dL, p < 0.001), and lower High-Density Lipoprotein (HDL) cholesterol (42 vs. 47 mg/dL, p = 0.002). SRM showed a positive correlation with IELT (r = 0.284, p = 0.010). No significant correlations were found with BMI or other lipid parameters. Conclusions: Lower serum spermidine synthase levels are significantly associated with acquired PE and shorter IELT. These findings suggest SRM as a potential novel biomarker and support further exploration of polyamine pathways in PE pathophysiology.
KW - spermidine synthase; premature ejaculation; polyamines; metabolic dysregulation; biomarker
DO - 10.32604/cju.2026.079146